Group 1 - The company plans to cancel 2,000,000 shares from its repurchased stock, reducing its registered capital from 512,053,647 yuan to 510,053,647 yuan [1][2] - The company had previously repurchased 10 million shares for employee stock ownership plans, completing the buyback on September 23, 2022 [1][2] - The cancellation of shares is intended to boost earnings per share and enhance shareholder returns, while not significantly impacting the company's financial status or future development [2] Group 2 - The remaining 2,000,000 shares in the repurchase account will expire on September 22, 2025, and have not been used for employee stock ownership plans [2] - After the cancellation, the total number of shares will decrease from 512,053,647 to 510,053,647 [2] - The company's equity distribution will still meet listing requirements, ensuring no change in its listing status [2]

General Provisions - The company, Transwarp Technology (Shanghai) Co., Ltd., is established to meet the needs of modern enterprise systems and to protect the rights and interests of the company, shareholders, employees, and creditors [2][3] - The company is registered in Shanghai and has obtained a business license with a unified social credit code [2] - The company was registered by the China Securities Regulatory Commission (CSRC) for the initial public offering of A shares and H shares [3][4] Business Objectives and Scope - The company's business objective is to become a global leader in big data and artificial intelligence foundational software [5] - The registered business scope includes import and export of goods, technology services, software development, and computer system services [6] Shares - The company's shares are issued in the form of registered stocks, with each share having a nominal value of RMB 1 [8][19] - The total number of shares after the initial public offering of H shares is projected to be 8,470.5989 million shares, all of which are ordinary shares [10] Shareholders and Shareholder Meetings - Shareholders have the right to request the company to provide relevant materials and to participate in shareholder meetings [16][17] - The company must hold an annual general meeting within six months after the end of the previous fiscal year [49] - The company’s shareholder meetings can be held in a combination of physical and online formats [31] Rights and Obligations of Shareholders - Shareholders are entitled to dividends and other forms of profit distribution based on their shareholding [38] - Shareholders must comply with laws and regulations and are prohibited from abusing their rights to harm the interests of the company or other shareholders [41][42] Control and Management - The controlling shareholders and actual controllers must exercise their rights in accordance with laws and regulations, ensuring the interests of the listed company are maintained [43] - The board of directors is responsible for managing the company and must act in the best interests of the company and its shareholders [46]

Core Viewpoint - The announcement details that the first lock-up period of the 2024 employee stock ownership plan of Yinchuan Weili Transmission Technology Co., Ltd. has not met the performance assessment targets, resulting in no shares being unlocked during this period [1][3]. Group 1: Employee Stock Ownership Plan Overview - The 2024 employee stock ownership plan was approved during meetings held on July 2, 2024, and July 18, 2024, with relevant resolutions passed [1]. - The plan involves a total of 335,366 shares, which represents 0.46% of the company's total share capital, transferred to the employee stock ownership plan on July 30, 2024 [2]. - The plan has a duration of 48 months, starting from July 30, 2024, and ending on July 29, 2028 [2]. Group 2: Performance Assessment and Future Arrangements - The first lock-up period's performance assessment did not meet the required targets, resulting in a 0% unlock rate and 67,074 shares remaining locked [3]. - The management committee will sell the unallocated shares and return the original investment amount to the holders, with any remaining profits belonging to the company [3]. - The plan remains in effect, and the company will adhere to market trading rules and relevant regulations regarding stock trading [4]. Group 3: Plan Changes and Termination - Any changes to the employee stock ownership plan require approval from at least two-thirds of the holders and must be submitted to the board for review [4]. - The plan can be terminated early if all assets are transferred to individual accounts or if the assets are entirely in cash, subject to the same two-thirds approval requirement [4]. Group 4: Ongoing Monitoring - The company will continuously monitor the implementation of the employee stock ownership plan and fulfill its information disclosure obligations in accordance with relevant laws and regulations [4].

Core Viewpoint - The company, Wuhan Changying Tong Optoelectronic Technology Co., Ltd., has announced a share repurchase plan aimed at implementing an employee stock ownership plan or equity incentives, with a total repurchase amount expected to be between 20 million and 40 million RMB [1][2][3] Summary by Sections Repurchase Plan Details - The repurchase plan was first disclosed on July 18, 2024, proposed by the controlling shareholder and chairman, Pi Yabin [1] - The implementation period for the repurchase is from July 17, 2024, to July 16, 2025 [1] - The maximum repurchase price is set at 33.13 RMB per share [2] - The total expected repurchase amount ranges from 20 million to 40 million RMB [2] Implementation Status - As of the latest report, the company has repurchased a total of 1,128,759 shares, accounting for 0.9224% of the total share capital [3][4] - The actual repurchase price ranged from 16.10 RMB to 27.11 RMB per share, with a total expenditure of approximately 22.85 million RMB [4] Shareholder and Management Transactions - During the repurchase period, there was a transaction involving a board member, who sold 48,000 shares, representing 0.0392% of the total share capital [4][5] Share Structure Changes - Before the repurchase, the company had 29,309,657 restricted shares (23.95%) and 93,064,769 unrestricted shares (76.05%) [5] - After the repurchase, the number of restricted shares decreased to 27,851,850 (22.76%), while unrestricted shares increased to 94,522,576 (77.24%) [5] Future Plans for Repurchased Shares - The repurchased shares will be used for employee stock ownership plans or equity incentives, with a requirement to complete the transfer within three years [6]

Group 1: Company Overview and R&D - The company’s R&D expenses for 2024 are expected to increase by 10% year-on-year, focusing on the development of raw materials and formulations, as well as process optimization and technological innovation for mature products like vitamins [1] - The company has officially started selling para-hydroxyphenol in the PEEK field and is actively promoting its products, having completed sample submissions to major domestic PEEK manufacturers, currently in various validation stages [1] Group 2: Product Registration and Market Activities - The company holds registration certificates for two products: Fumaric Acid Bisoprolol Tablets and Lacosamide Injection, with the former having commenced market promotion and industrialization in 2024 [1] - There are currently no plans for stock incentive programs or share buybacks, although the company previously repurchased shares in 2019 and conducted a restricted stock incentive plan in 2015, along with the first employee stock ownership plan launched in 2021 [2] Group 3: Inventory and Capital Expenditure - The company’s large ending inventory balance is attributed to its diverse business segments, including vitamins, flavors, raw materials, leather chemicals, and chromium salts, consisting mainly of raw materials, work-in-progress, and finished products to meet varying customer demands [2] - Future capital expenditures will primarily focus on new project construction, such as a 600-ton iodinated contrast agent raw material project, and technological upgrades to existing projects aimed at cost reduction, efficiency enhancement, and improved safety and environmental control [2] Group 4: Risk Management - The company has not engaged in hedging activities and currently sees no demand for such services [2]

Meeting Overview - The first meeting of the 2025 Employee Stock Ownership Plan (ESOP) was held on July 16, 2025, with 23 participants representing 8,050,000 shares, which constitutes 100% of the total shares in the plan [1][2]. Resolutions Passed - The meeting approved the establishment of a management committee for the 2025 ESOP to enhance daily management efficiency, consisting of three members, including a chairperson [2][3]. - The committee members elected are Hua Xiangyang, Yao Hongxia, and Zheng Xinnian, with their term aligned with the duration of the 2025 ESOP [2][3]. - The management committee was authorized to handle all matters related to the 2025 ESOP, including asset liquidation and handling of disqualified holders' shares, with a unanimous approval of 8,050,000 shares [3].

Meeting Overview - The first meeting of the 2023 Employee Stock Ownership Plan (ESOP) was held on July 16, 2025, with 18 participants representing 8,817,978.20 shares, accounting for 100% of the voting rights [1][2] - The meeting was convened and presided over by the company's board secretary, Huang Rongfang, and complied with relevant laws and regulations [1] Resolutions Passed - The establishment of the 2023 ESOP Management Committee was approved to ensure the smooth implementation of the plan and protect the rights of the holders [1] - The committee will consist of three members, including one chairperson, with a term lasting for the duration of the ESOP [1] Voting Results - The resolution to establish the management committee received unanimous approval, with 8,817,978.20 votes in favor, representing 100% of the valid voting rights [2][3] - No votes were cast against or abstained from this resolution [2][3] Committee Elections - The election of Yang Xinping, Yan Xinhua, and Li Bin as members of the 2023 ESOP Management Committee was approved, with their term aligned with the ESOP duration [2] - The committee held its first meeting on the same day, electing Yang Xinping as the chairperson [2] Authorization - The meeting authorized the 2023 ESOP Management Committee to handle matters related to the ESOP, including changes in holders and share adjustments, effective until the termination of the ESOP [2]

Core Viewpoint - The company has successfully completed the first lock-up period of its 2024 employee stock ownership plan, allowing 45 eligible participants to unlock 30% of the initially granted shares, totaling 1.467 million shares, which represents 0.17% of the company's total share capital [2][7]. Implementation of Employee Stock Ownership Plan - The company held board meetings on June 14, 2024, and July 1, 2024, to approve the implementation of the employee stock ownership plan [2]. - On July 16, 2024, the company transferred 5.551 million shares to the dedicated account for the employee stock ownership plan, which accounted for 0.65% of the total share capital at that time [3]. - The stock ownership plan has three unlocking phases, with the first phase's unlocking conditions met on July 16, 2025 [3][4]. Performance Assessment - The performance assessment for the first lock-up period included company-level targets for revenue and innovation drug development progress [4]. - The company achieved its innovation drug development goals, with significant progress in clinical trials for multiple drugs, resulting in a 100% unlocking ratio for this performance metric [5][6]. - Individual performance assessments for the 45 participants were all rated B+ or above, meeting the criteria for full unlocking [7]. Future Arrangements - Following the unlocking of the first lock-up period, the employee stock ownership management committee will manage the rights of the participants according to the authorized decisions made in the meetings [8]. - The company will adhere to market trading rules and relevant regulations regarding stock transactions [8].

Core Points - The company has decided to extend the duration of its employee stock ownership plan by 12 months, now set to expire on July 17, 2026, based on the confidence of the plan holders in the company's stable development and stock value [1][2]. Group 1 - The first meeting of the employee stock ownership plan holders was held, with all 3 attendees representing 100% of the voting rights [1]. - The meeting's procedures complied with relevant regulations and the company's employee stock ownership plan [1]. - The voting results showed unanimous support for the extension, with 815,553 shares in favor, representing 100% of the votes cast [2].

Core Viewpoint - The company has decided to extend the duration of the Tai Chi Industrial • Eleven Technology Employee Stock Ownership Plan by an additional 12 months, now set to expire on July 17, 2026, following approval from the first holder meeting of 2025 and the 29th meeting of the 10th Board of Directors [1][4]. Summary of Employee Stock Ownership Plan - The employee stock ownership plan was initially approved in October 2015, allowing for the non-public issuance of up to 200 million shares [2]. - As of the latest announcement, the plan holds 815,553 shares, representing a small fraction of the company's total share capital [3]. - The plan has undergone several extensions since its inception, with the most recent extensions occurring in 2020, 2021, 2022, and 2023, each time adding 12 months to the original duration [2][4]. Approval Process - The extension of the employee stock ownership plan was approved unanimously by the Board of Directors, with 8 votes in favor and no opposition [4]. - The independent directors have also expressed their agreement with the extension, confirming that it aligns with regulatory guidelines and does not harm the interests of the company or its shareholders [5].